Portugal: 20% of all Covid-19 pandemic infections have occurred since BA.5 was first reported

BA.5, Coronavirus, Deaths, Europe, Genome, Healthcare, Hospitalization, Infection, Omicron, Portugal, Reinfection, Testing, Transmission, Vaccine Breakthrough, Vaccine Waning

The almost 990,000 confirmed cases in April and May 2022 represent 21% of infections since the beginning of the Covid-19 pandemic, while the 1,455 deaths constitute about 6% of total deaths.

In the last two months, the country has entered the sixth wave of the pandemic, recording, according to data from the Directorate-General for Health (DGS), a total of 988,307 cases: 288,059 in April and 700,248 in May, which means 21% of the infections notified by Portugal to the World Health Organization (WHO).

ThePortugalNews.com report

 

Over 20% of all Covid-19 infections have occurred since April 2022 in Portugal, following the arrival of BA.5:

 

Covid hospital patient numbers in Portugal levelled off in March 2022 and then started rapidly increasing again in mid-April 2022:

 

There was a noticeable change in Covid-19 deaths in Portugal at the end of March 2022:

 

 

CovSpectrum is showing BA.5 represents nearly 70% of all SARS-CoV-2 samples recently sequenced in Portugal

 

BA.5 started to increase in Portugal in early April 2022

 

BA.5 is looking like the SARS-CoV-2 subvariant that could displace BA.2

 

Looking at Raj Rajnarayanan’s BA.5 tracker, you can see that there are other countries have a growing B.5 problem, namely the UK, USA, Germany, Denmark,  Austria and Israel:

 

“The BA.5 subvariant’s share of cases is also on the rise in Germany, albeit from a lower level. According to a weekly news bulletin by Germany’s disease control agency, the Robert Koch Institute, BA.5’s share of cases has approximately doubled every week over the last month, from 0.2% of cases at the end of April to 5.2% by 22 May.”

Guardian report

 

On May 13th 2022, a European Centre for Disease epidemiological update predicted a summer wave driven by BA.4 and BA.5:

“The currently observed growth advantage for BA.4 and BA.5 is likely due to their ability to evade immune protection induced by prior infection and/or vaccination, particularly if this has waned over time. .

Taken together, this indicates that the presence of these variants could cause a significant overall increase in COVID-19 cases in the EU/EEA in the coming weeks and months. The overall proportion of BA.4 and BA.5 in the EU/EEA is currently low but the high growth advantages reported suggest that these variants will become dominant in the EU/EEA in the coming months. As in previous waves, if COVID-19 case numbers increase substantially, some level of increased hospital and ICU admissions is likely to follow.”

ECDC: Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5

 

 

Denmark: BA.5 up 135% in a month

 

 

 

Image by Pedro Grão from Pixabay

** This post was originally published on June 5, 2022 **